Skip to main content
SpringerLink
Log in

Immunologic Disorders of Neuromuscular Junction and Muscle

  • Chapter
  • First Online:
Clinical Neuroimmunology

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 1670 Accesses

Abstract

A range of inherited and acquired processes can adversely affect the ­neuromuscular junction (NMJ) and muscle, many of which are not amenable to medical therapy, such as the muscular dystrophies. Autoimmune disorders of NMJ and muscle provide some of the limited number of peripheral neuromuscular diseases responsive to medical therapy and thus, are essential to recognize. Immune disorders account for the most common diseases of neuromuscular transmission and are very important to understand, not least because the autoimmune nature of disease provides opportunities for effective treatment. On the other hand, inflammatory disorders of muscle are a diverse group, some of which appear to have an immunologic basis, e.g., polymyositis and dermatomyositis, and possibly, inclusion body myositis (IBM).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gilchrist JM. Neurophysiology of neuromuscular transmission and its disorders. In: Blum AS, Rutkove SB, editors. The clinical neurophysiology primer. New Jersey: Humana; 2007. p. 353–68.

    Chapter  Google Scholar 

  2. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci. 1987;505:472.

    Article  PubMed  CAS  Google Scholar 

  3. Grob D. Natural history of myasthenia gravis. In: Engel AG, editor. Myasthenia gravis and myasthenic disorders. New York: Oxford University Press; 1999. p. 131–45.

    Google Scholar 

  4. Holhlfeld R, Wekerle H. The immunopathogenesis of myasthenia gravis. In: Engel AG, editor. Myasthenia gravis and myasthenic disorders. New York: Oxford University Press; 1999. p. 87–110.

    Google Scholar 

  5. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304–11.

    Article  PubMed  Google Scholar 

  6. Limburg PC, The H, Hummel-Tappel E, Oosterhuis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part I: Their relation to the clinical state and the effect of therapy. J Neurol Sci. 1983;58:357.

    Article  PubMed  CAS  Google Scholar 

  7. Seybold ME. Treatment of myasthenia gravis. In: Engel AG, editor. Myasthenia gravis and myasthenic disorders. New York: Oxford University Press; 1999. p. 167–204.

    Google Scholar 

  8. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007;(4):CD005224.

    Google Scholar 

  9. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008;(1):CD002277.

    Google Scholar 

  10. Rowin J, Meriggioli MN, Tüzün E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependant myasthenia gravis. Neurology. 2004;63:2390–2.

    PubMed  CAS  Google Scholar 

  11. O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic ­syndrome: a review of 50 cases. Brain. 1988;111:577–96.

    Article  PubMed  Google Scholar 

  12. Titulaer M, Wirtz PW, Kuks JB, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture of 97 patients. J Neuroimmunol. 2008;201–202:153–8.

    Article  PubMed  Google Scholar 

  13. Comola M, Nemni R, Sher E, et al. Lambert-Eaton myasthenic syndrome and polyneuropathy in a patient with epidermoid carcinoma of the lung. Eur J Neurol. 1993;33:121–5.

    Article  CAS  Google Scholar 

  14. Chalk CH, Murray NM, Newsom-Davis J, O’Neill JH, Spiro S. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small cell lung carcinoma. Neurology. 1990;40:1552–6.

    PubMed  CAS  Google Scholar 

  15. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104:359–63.

    Article  PubMed  Google Scholar 

  16. Newsome-Davis J, Lang B. The Lambert-Eaton myasthenic syndrome. In: Engel AG, editor. Myasthenia gravis and myasthenic disorders. New York: Oxford University Press; 1999. p. 205–28.

    Google Scholar 

  17. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000;54:2176–8.

    PubMed  CAS  Google Scholar 

  18. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic ­syndrome. Cochrane Database Syst Rev. 2005;(2):CD003279.

    Google Scholar 

  19. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.

    Article  PubMed  CAS  Google Scholar 

  20. Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord. 2006;16:223–36.

    Article  PubMed  Google Scholar 

  21. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndrome. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 1994. p. 1335–83.

    Google Scholar 

  22. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16:193–208.

    Article  PubMed  CAS  Google Scholar 

  23. Imbert-Massaeu A, Hamidou M, Agard C, Grolleau JY, Chérin P. Antisynthetase syndrome. Joint Bone Spine. 2003;70:161–8.

    Article  Google Scholar 

  24. Sordet C, Goetz J, Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine. 2006;73:646–54.

    Article  PubMed  CAS  Google Scholar 

  25. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002;73:420–8.

    Article  PubMed  CAS  Google Scholar 

  26. Dimitri D, Andre C, Roucoules J, Hosseini H, Humbel RL, Authier FJ. Myopathy associated with anti-signal recognition peptide antibodies: Clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve. 2007;35:389–95.

    Article  PubMed  Google Scholar 

  27. Choy EHS, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2005;(3):CD003643.

    Google Scholar 

  28. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: observations in 40 patients. Brain. 1989;112:727–47.

    Article  PubMed  Google Scholar 

  29. Joy JL, Oh SJ, Baysal AI. Electrophysiological spectrum of inclusion body myositis. Muscle Nerve. 1990;13:949–51.

    Article  PubMed  CAS  Google Scholar 

  30. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol. 1988;23:168–73.

    Article  PubMed  CAS  Google Scholar 

  31. Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor ­expression by infiltrating lymphocytes in inclusion body myositis persists over time. Brain. 2000;123:2030–9.

    Article  PubMed  Google Scholar 

  32. Liu LW, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol. 2004;18:397–9.

    PubMed  Google Scholar 

  33. Brown RH, Amato AA. Calpainopathy and eosinophilic myositis. Ann Neurol. 2006;59:875–7.

    Article  PubMed  Google Scholar 

  34. Krahn M, Lopez de Munain A, Streichenberger N, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol. 2006;59:905–11.

    Article  PubMed  CAS  Google Scholar 

  35. Pegoraro E, Mancias P, Swerdlow SH, et al. Congenital muscular dystrophy with primary laminin a2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol. 1996;40:782–91.

    Article  PubMed  CAS  Google Scholar 

  36. McNally EM, Ly CT, Rosenmann H, et al. Splicing Mutation in Dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet. 2000;91:305–12.

    Article  PubMed  CAS  Google Scholar 

  37. Arahata K, Ishihara T, Fukunaga H, et al. Inflammatory response in fascioscapulohumeral muscular dystrophy (FSHD): Immunocytochemical and genetic analyses. Muscle Nerve. 1995;Suppl 2:S56–66.

    Google Scholar 

  38. Barnard J, Newman LS. Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol. 2001;13:84–91.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Rhode Island Hospital, Warren Alpert Medical School at Brown University, Providence, RI, USA

    Kara A. Chisholm MD & James M. Gilchrist MD

  2. Department of Pathology, Division of Neuropathology, Rhode Island Hospital, Department of Pathology and Laboratory Medicine, Warren Alpert Medical School at Brown University, Providence, RI, USA

    John E. Donahue MD

Authors
  1. Kara A. Chisholm MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James M. Gilchrist MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John E. Donahue MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M. Gilchrist MD .

Editor information

Editors and Affiliations

  1. , Department of Clinical Neuroscience, Brown University, Dudley Street 2, Providence, 02905, Rhode Island, USA

    Syed A. Rizvi

  2. Stony Brook Medical Center, Department of Neurology, State University of New York, Belle Meade Rd. 179, East Setauket, 11733, New York, USA

    Patricia K. Coyle

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chisholm, K.A., Gilchrist, J.M., Donahue, J.E. (2011). Immunologic Disorders of Neuromuscular Junction and Muscle. In: Rizvi, S., Coyle, P. (eds) Clinical Neuroimmunology. Current Clinical Neurology. Humana Press. https://doi.org/10.1007/978-1-60327-860-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-860-7_18

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-859-1

  • Online ISBN: 978-1-60327-860-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation